Browse the corpus

Lurasidone is a second-generation (atypical) antipsychotic in the benzisothiazole class, indicated for the treatment of schizophrenia and bipolar depression. The drug has a distinct receptor-binding profile that differentiates it from other antipsychotics. This activity provides a comprehensive understanding of the complex pharmacology, FDA-approved indications, mechanism of action, contraindications, boxed warnings, adverse effects, dosing, monitoring, and drug interactions of lurasidone. Emphasis is placed on evidence-based strategies to optimize treatment outcomes, minimize adverse events, and deliver patient-centered care in both monotherapy and adjunctive treatment settings. This activity provides healthcare professionals with essential knowledge and practical tools for the safe and effective use of lurasidone, underscoring their critical role in supporting patient care. By combining pharmacologic knowledge with collaborative practice, interprofessional healthcare providers can collaborate to individualize therapy, enhance safety, and improve clinical outcomes. This training enables healthcare professionals to apply evidence-based medicine effectively, maximize the therapeutic benefits of lurasidone, mitigate risks, and work efficiently within a coordinated healthcare team. Objectives: Identify FDA-approved indications, contraindications, and off-label uses of lurasidone for schizophrenia and bipolar depression. Implement evidence-based dosing strategies for both adult and pediatric populations, including adjustments for renal or hepatic impairment. Select appropriate patients for monotherapy or adjunctive therapy with lithium or valproate. Collaborate with the healthcare team to coordinate monitoring, manage adverse effects, and optimize safe, individualized lurasidone therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Data on lurasidone overdose are limited. A literature search revealed only one case report of acute lurasidone overdose. This case report describes an adult man aged 31 who overdosed on large amounts of lurasidone in an attempt to commit suicide. The quantity of lurasidone ingested was 8.5 times the upper maximum limit. The overdose occurred shortly after lunch, which increased the absorption of lurasidone. The patient presented with mild hypertension and slightly elevated TSH levels. The patient only required IV fluids and recovered without sequelae. TSH levels normalized within 3 weeks after the overdose.[40] In the FDA-approved product labeling for lurasidone, there is a documented case report of an overdose. A patient ingested 560 mg of lurasidone and subsequently recovered without any negative sequelae. Clinicians involved in the case noted that there were no long-term adverse effects from the lurasidone overdose. Management of Overdose Currently, specific antidotes for lurasidone are not available. In cases of overdose, close monitoring is recommended for the prolongation of the QT interval, orthostatic hypotension, central nervous system depression, and tachycardia.[44] Hypotension and circulatory collapse should be managed with appropriate supportive measures. Epinephrine, dopamine, or other beta-agonist sympathomimetics should be avoided, as beta stimulation may worsen hypotension in the setting of lurasidone-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication such as benzhexol (trihexyphenidyl) should be administered. Tardive dyskinesia can be treated with a VMAT2 inhibitor such as valbenazine. For seizures, benzodiazepines may be administered. For neuroleptic malignant syndrome, aggressive intravenous hydration, benzodiazepines, dantrolene, and bromocriptine are recommended.[45]

Lurasidone is clinically beneficial in treating patients with schizophrenia and bipolar depression.[46] Approximately 80% of patients with schizophrenia achieve an optimal response at doses of 40 to 80 mg of lurasidone per day. Lurasidone has also been shown to improve depressive symptoms in patients with schizophrenia, which is particularly important given the association between depression and suicide risk in this population.[47] Additional clinical trials are necessary to confirm any potential antisuicidal effects of lurasidone. Patients with bipolar depression typically achieve an optimal clinical response with lurasidone at 20 to 60 mg per day. Although lurasidone has minimal metabolic adverse effects, it can cause akathisia, somnolence, sedation, and extrapyramidal adverse effects. These effects can be minimized by using an appropriate dose and administering the medication in the evening. Although lurasidone does not significantly prolong the QTc interval, most sudden cardiac deaths in patients receiving atypical antipsychotics are dose-dependent. Therefore, careful monitoring is required when prescribing higher doses of lurasidone. Lurasidone offers the convenience of once-daily dosing, which is especially important for patients suffering from complex mental illnesses. Healthcare providers, including pharmacists, play a critical role in counseling patients to take the medication with a meal of at least 350 calories to enhance absorption. For patients who find these dietary requirements challenging, developing a water-soluble formulation of lurasidone could help improve absorption.[48] In acute schizophrenia, lurasidone demonstrated efficacy comparable to quetiapine but was not superior to risperidone in 12-month studies. Data on its effectiveness in bipolar depression are more limited. In 2014, 2 randomized, double-blind clinical trials (PREVAIL) showed that lurasidone, both as monotherapy and as an adjunct to lithium or valproate, significantly reduced scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression for use in bipolar illness (CGI-BP).[3][49] More recently, in 2017, a randomized, placebo-controlled trial of lurasidone monotherapy in children and adolescents demonstrated a significant decrease in depressive and anxiety symptoms, along with improvements in overall quality of life.[50]

In acute schizophrenia, lurasidone demonstrated efficacy comparable to quetiapine but was not superior to risperidone in 12-month studies. Data on its effectiveness in bipolar depression are more limited. In 2014, 2 randomized, double-blind clinical trials (PREVAIL) showed that lurasidone, both as monotherapy and as an adjunct to lithium or valproate, significantly reduced scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression for use in bipolar illness (CGI-BP).[3][49] More recently, in 2017, a randomized, placebo-controlled trial of lurasidone monotherapy in children and adolescents demonstrated a significant decrease in depressive and anxiety symptoms, along with improvements in overall quality of life.[50] Data on the safety and efficacy of lurasidone use in older and pregnant or postpartum women are limited. Clinical studies in patients with schizophrenia indicate that lurasidone is generally well tolerated, with minimal adverse effects. However, additional high-quality, long-term randomized controlled trials are needed to establish its safety and efficacy in the treatment of bipolar depression. Lurasidone therapy is most effective when managed by a coordinated healthcare team. The prescribing clinician initiates treatment based on clinical judgment, while nursing staff play a key role in counseling patients on dosing and administration, monitoring treatment progress during follow-up visits, and communicating any concerns to the prescriber. Pharmacists contribute by checking for potential drug–drug interactions, particularly given lurasidone’s CYP450 metabolism, verifying proper dosing, and providing additional patient counseling at the time of medication dispensing. In cases of overdose, emergency medicine and critical care teams stabilize the patient promptly, with toxicology consultation for complex situations. Ongoing patient monitoring and support are essential components of therapy. Nurses ensure consistent follow-up, address patient questions, and report observations to the managing clinician. Optimal therapeutic outcomes are achieved through collaboration among an interprofessional healthcare team, including physicians, advanced practice providers, psychiatrists, clinical psychologists, specialty-trained nurses, and pharmacists, all communicating effectively to tailor treatment and ensure patient safety.